About
Mark Timney is a biopharmaceutical executive who has led Purdue Pharma, The Medicines Company, and Attralus. At The Medicines Company, he became CEO in December 2018 and led the company through the Novartis acquisition completed in 2020. As of July 2, 2026, Attralus lists him as its Chief Executive Officer and a member of its Board of Directors, focused on systemic amyloidosis therapies.
Areas of interest
biotechpharmaceuticalsrare diseaseamyloidosiscardiovascular therapeuticscentral nervous system disordersdrug commercializationclinical developmentstrategic transactionsboard governance